Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone versus topical nepafenac for acute central serous chorioretinopathy
IRCT20240404061413N1Phase 2Completed
- Sponsor
- Al-Shifa Trust Eye Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of eplerenone and nepafenac in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by Al-Shifa Trust Eye Hospital. Primary endpoints: Resolution of visual acuity and Resolution of subretinal fluid. Started Apr 2024; status: completed.
02
Drugs
eplerenonenepafenac
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on IRCT20240404061413N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240404061413N1.